ReAIX Platform Featured in Major Media Coverage at COMPUTEX 2026 and NVIDIA GTC
ReAIX was covered by leading media during COMPUTEX 2026 and NVIDIA GTC, where investor and partner Compal Electronics presented its quantum AI work for drug discovery.
On June 4, 2026, the ReAIX platform was featured at COMPUTEX 2026 and NVIDIA GTC and covered by international and Taiwanese media, including PR Newswire, Commercial Times, Liberty Times, MoneyDJ and TTV Finance.
Compal's keynote at NVIDIA GTC
Compal Electronics (2324), an investor and partner of Vernus AI, issued a global press release and gave a keynote at NVIDIA GTC on accelerating drug discovery with quantum AI and supercomputing. Compal showed its CGA-QX Docking system, which combines CUDA-Q quantum simulation with GPU acceleration and runs up to 3,500 times faster than traditional molecular docking.
ReAIX in the coverage
Coverage highlighted the role of Vernus AI in turning quantum computing and AI into practical value for industry. ReAIX integrates AI, quantum computing and physics simulation for drug manufacturing. It is built on NVIDIA NeMo Agent Toolkit and PhysicsNeMo and supports process optimization from lab scale to manufacturing scale.
ReAIX has completed several projects with pharmaceutical companies in Taiwan and abroad, including Orient EuroPharma, shortening development timelines and reducing production costs.
Sources and coverage
About Vernus AI
Vernus AI (睿泉生技) builds ReAIX, a family of platforms that combine AI, physics-based simulation and annealing-based optimization to help pharmaceutical teams find better process conditions with fewer experiments.